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Abstract  
Background: In ABO-incompatible kidney transplantation, the diagnostic criteria for antibody-
mediated rejection remain controversial because C4d deposition is commonly observed. Thus, we 
investigated microvascular inflammation (MVI score ≥ 2) within one year as a predictor of graft 
outcome.  
Methods: A total of 148 recipients without preformed or de novo donor-specific anti-HLA antibody 
were stratified based on MVI score < 2 (n = 117) and MVI score ≥ 2 (n = 31).  
Results: We found that 5-year graft survival was significantly lower (p = 0.0129) in patients with MVI 
(89.8 %) than in patients without MVI (97.0 %). Graft function, as characterized by serum estimated 
glomerular filtration rate, was also significantly worse for patients with MVI than it was for patients 
without MVI, between 3 months and 10 years after transplantation (p = 0.048). Multivariate analysis 
indicated that HLA class II mismatch (p = 0.0085) was an independent marker of MVI.  
Conclusions: MVI score ≥ 2 is significantly associated with poor graft outcome following ABO-
incompatible kidney transplantation. We suggest that MVI score ≥ 2 in ABOi transplantation be used 
as a basis to diagnose AMR.  
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Introduction 
 A serious shortage of organ donors has persisted in Japan over several decades despite widespread 
efforts to promote kidney donation at death 1-3. To overcome this issue, transplantation across the ABO 
blood type barrier has been attempted in Japan 2 and throughout the world 4, and we have devised 
immunosuppressive regimens and protocols to ensure effectivity and safety 3,5-7. Recent systematic 
reviews also suggest that the modern preconditioning therapies, including administration of rituximab, 
immunoadsorption, and apheresis therapy, contribute to the achievement of graft outcomes equivalent 
to those achieved by ABO compatible transplantation 8,9. In the end, ABO-incompatible (ABOi) 
kidney transplantation promotes increased use of limited resources.  
Anti-blood type antibodies were previously considered a lethal factor driving hyper-acute rejection 
or graft-loss in cases of ABOi transplantation. However, over the course of developing 
immunosuppressive regimens, neither preoperative nor postoperative anti-blood type antibodies were 
observed to influence graft outcome in ABOi transplantation10,11. Rather than anti-blood type 
antibodies, we suggested that donor-specific anti-HLA antibodies (DSA) were a significant factor 
driving development of antibody-mediated rejection (AMR), and a predictor of inferior graft outcome 
in ABOi transplantation12. Bentall et al. also suggested that positive crossmatch kidney 
transplantations had significantly worse graft outcomes than ABOi transplantations13. Moreover, an 
immunohistochemical study of a human ABOi transplant sample revealed that the endothelium injury 
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due to blood-type antigen did not impact the long-term graft outcome 14.  
AMR is a critical, well-known determinant of graft survival 6,12,15-17, and is typically diagnosed 
according to the Banff criteria, which include microvascular inflammation (MVI), C4d deposition, 
and DSA 18,19. When diagnosing AMR in transplantation of standard immunological risk, the presence 
of C4d deposition is regarded as an effective marker 20,21. However, because C4d deposition is 
commonly observed in ABOi transplantation, its diagnostic value remains controversial 6,17,22. Couzi 
et al.23 reported that 13/30 (43.3%) patients with C4d deposition have no rejection of ABOi 
transplantation. Using 89 biopsies from ABOi transplantations, Setoguchi et al. 6 reported C4d 
deposition in 94% of the studies patients (C4d 3 was in 66%), although AMR occurs for only 27% of 
these patients. Moreover, a novel immunosuppressive agent such as eculizumab, which is an antibody 
against C5 that blocks the terminal complement cascade, may cause difficulty in using C4d deposition 
to diagnose AMR 24,25. In this context, the role of C4d deposition as an indicator of AMR seems unclear. 
Thus, MVI score ≥ 2 may be a more important indicator than C4d presence for diagnosing AMR in 
the ABOi transplant population. MVI, which typically presents as glomerulitis and peritubular 
capillaritis, is considered a strong indicator, with MVI score ≥ 2 sometimes used to diagnose rejection 
even in the absence of C4d deposition 21 as long as DSAs are also detected19. MVI score ≥ 2 with 
circulating DSA correlates with transplant glomerulopathy independently of C4d deposition. MVI 
score ≥ 2 is also associated with other pathologies such as glomerulonephritis 21,26. Accordingly, MVI 
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score ≥ 2 is regarded as a significant predictor of graft outcome 19-21,27,28. This impact has been 
demonstrated for standard immunological risk, but not ABOi transplantations. 
To clearly define the diagnostic value of MVI score ≥ 2 regardless of C4d deposition, we investigated 
the relationship between MVI score ≥ 2 and graft outcome in ABOi patients without preformed or de 
novo DSA.  
 
Materials and Methods 
Study design and patients 
 Between January 2001 and January 2015, a total of 227 patients at our department and affiliated 
institutions received ABOi kidney transplants from living relatives. Several patients were excluded 
due to preformed (n = 55) and de novo (n = 1) DSA within one year after transplantation, as indicated 
by fluorescence intensity > 1,000 on a Luminex single-antigen beads assay (One Lambda Inc., Canoga, 
Park, CA, USA). Patients without allograft biopsy within one year after transplantation (n = 20), were 
also excluded, as were three patients with missing data. During follow-up, de novo DSA developed in 
one patient after 15 months (DR13), and in another patient after 33 months (DQ6). These two patients 
were included in the analysis, which was based on pathological findings within one year following 
transplantation.  
The remaining 148 recipients were stratified into two groups based on MVI score < 2 (n=117) and 
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MVI score ≥ 2 (n = 31, Figure 1). The threshold ≥ 2 was selected, because the aim was to evaluate the 
impact of MVI on graft outcome independent of C4d deposition 19, which was defined to be focal or 
diffuse C4d score ≥ 2. Clinical and laboratory data were extracted from an electronic database and 
from medical records. If multiple biopsies were obtained from a patient, the highest score was used to 
determine MVI status. The MVI score was calculated as the sum of g (glomerulitis) and ptc 
(peritubular capillaritis) scores. Recipients who lost grafts were excluded from analysis at timepoints 
beyond loss of the graft. All study procedures were approved by the Institutional Review Board of 
Tokyo Women’s Medical University (ID: 3824), and were in accordance with the Declaration of 
Helsinki and Istanbul 2008.  
 
Graft function 
 Graft function was compared between groups based on serum estimated glomerular filtration rate 
(eGFR) at various timepoints after transplantation. eGFR was calculated according to the formula 
developed by the Japanese Society of Nephrology 29, in which eGFR (mL/min/1.73m2) = 194 × [Serum 
creatinine (mg/dL)]-1.094 × [Age (year)]-0.287 (× 0.739, if female). 
 
Immunosuppressive and desensitization protocols 
 Multiple immunosuppressive and desensitization protocols, shown in Figure 2, are used in our 
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institutions. Immunosuppressive regimens, in which recipients were administered tacrolimus, 
mycophenolate mofetil, and methylprednisolone, have been described in detail previously 3,5. After 
2002, recipients also received basiliximab perioperatively 7. Splenectomy was performed during 
transplantation until 2004, after which point rituximab was administered instead, at an intravenous 
dose of 200 mg per person 5-7 days before transplantation 30,31.    
 
Removal of anti-blood type antibodies 
To remove anti-blood type antibodies, recipients underwent 3-4 sessions of double plasmapheresis 
before transplantation 3,5,11. Plasmapheresis was performed using OP-05H (ASAHI Medical Co. Ltd., 
Osaka, Japan) and Evaflux 2A (Kuraray Co Ltd., Osaka, Japan) plasma separators until titers decreased 
to 1:32 or below.  
Anti-blood type IgG is difficult to detect by hemagglutination of pentameric IgM. Thus, we have 
developed an ELISA assay specific for anti-blood type IgG. However, indirect Coomb’s test was used 
instead to measure IgG titers every other month, as the ELISA assay is not yet accepted worldwide. 
IgM against blood type A and B was quantified using saline and/or Bromerin agglutination techniques, 
as specified in our protocol.  
  
Routine and for-cause biopsy 
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 Written informed consent for biopsy was obtained from all patients. As previously described 6, 
patients with stable allograft function underwent biopsy 1, 3, 6, and 12 months after transplantation, 
and then yearly, if possible.  
All patients underwent monthly follow-up blood examinations. For-cause biopsy was performed only 
if serum creatinine is measured at < 2 mg/dL, proteinuria less than 1 g/day is observed, and kidney 
function is unstable, as indicated by > 15 % variation in serum creatinine two weeks before and after 
biopsy. That is, variation in post biopsy serum creatinine, or decreasing serum creatinine, are not 
always indications for additional biopsy. 
 Two core biopsies were obtained under ultrasound guidance using a spring-loaded 16-gauge biopsy 
gun. One biopsy was snap-frozen, while the other was fixed in 10 % formalin, embedded in paraffin, 
serially sectioned at 3 µm, and stained with hematoxylin and eosin, Masson trichrome, periodic acid-
Schiff, and periodic acid-methenamine silver. Tissues were examined under a light microscope by the 
same blinded pathologist, and scored using Banff’09 18 and ‘13 classification 19. A biopsy with seven 
or more glomeruli and at least one arterial cross-section was considered adequate, and unsatisfactory 
specimens were excluded from analysis.   
 
C4d staining in the peritubular capillaries  
C4d staining was routinely performed on all renal allograft biopsies by indirect immunofluorescence 
12 
 
on cryostat sections. The staining used a mouse monoclonal anti-human C4d antibody (Quidel, San 
Diego, CA) at 1:40 dilution, followed by fluorescein isothiocyanate-conjugated goat anti-mouse IgG. 
Peritubular capillaritis C4d stain extent and intensity were evaluated semi-quantitatively as follows: 
negative (< 25% of ptc C4d stained), focal C4d positive (≥ 25% of specimen but < 75%) or diffuse 
and bright C4d staining (nearly all ptc in the cortex and medulla). We also examined pre-transplant 
biopsies by immunofluorescence microscopy.  
 
Statistical analysis 
Continuous variables were analyzed by Mann-Whitney U-test, and categorical variables were 
analyzed by χ2 or Fisher’s exact test. Graft survival was calculated using Kaplan-Meier methods, and 
compared using the log-rank test and Wilcoxon’s test, respectively. Graft survival after transplantation 
was defined as the time between transplantation and graft loss due to any cause.. Univariate and 
multivariate logistic regression were used to identify predicators of MVI score Graft function 
according to mean serum eGFR was compared using a mixed-effects model for repeated-measures 
data ≥ 2. Risk was expressed in odds ratios and 95 % confidence intervals. An independent statistical 
data center (STATZ Institute, Tokyo, Japan) performed the analysis using JMP® 11 (SAS Institute Inc., 
Cary, NC, USA), and SAS 9.1 (SAS Institute Inc., Cary, NC, USA) software packages. Differences 
with p-value < 0.05 were considered statistically significant. 
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Results 
Patient characteristics  
Patient characteristics with (MVI score ≥ 2) or without MVI (MVI score < 2) are summarized in 
Table 1. There were no significant differences in clinical characteristics including recipient age and 
sex, kidney disease, duration of dialysis, donor age and sex, and follow-up period (all p > 0.05). There 
were also no significant differences in immunological parameters such as ABO group (p = 0.498), 
HLA class I mismatch, and baseline, preoperative, and postoperative anti-blood group IgG (all p > 
0.05). However, HLA class II mismatch was significantly more frequent in patients with MVI score ≥ 
2 (p = 0.0072). In addition, all patients also appeared to have received comparable immunosuppressive 
treatments, and there were no significant differences in basiliximab induction, rituximab induction, 
splenectomy status, and preoperative double plasmapheresis (all p > 0.05). However, patients with 
MVI score ≥ 2 underwent significantly more allograft biopsies (p < 0.0001). In addition, one patient 
from each group had de novo DSA after the first post-transplantation year (1 patient out of 31, or 
3.23%, for the MVI ≥ 2 group; for the MVI < 2 group. 1/117, or 0.85%).  
 
Graft survival  
 Graft survival in patients with high or low MVI score is plotted as Kaplan-Meier curves in Figure 3. 
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Graft survival over five years was significantly lower in patients with MVI score ≥ 2 than it was in 
patients with low MVI scores, according to Wilcoxon’s test (89.8 % vs. 97.0 %, p = 0.0129). The log-
rank test indicated only a marginal graft survival difference between these two groups (p = 0.0878). 
Grafts were lost during this period in three recipients with MVI score < 2, and in three recipients with 
MVI ≥ 2. In the former, grafts were lost at 1786 days, 3293 days, and 253 days, respectively, due to 
recurrent focal segmental glomerulosclerosis, choric rejection, and vascular rejection. In the latter, 
grafts were lost at 20 and 1 day due to hyper-acute rejection, and at 325 days due to choric rejection. 
For the MVI score ≥ 2 treatment, we performed steroid pulse, intravenous immunoglobulin therapy, 
and plasmapheresis for 29 (93.5%), 6 (19.4%), and 3 (9.68%) patients, respectively. We administered 
additional rituximab, deoxyspergualin, and muromonab-CD3 for 4 (12.9%), 6 (19.4%), and 3 (9.68%) 
patients, respectively.   
 
Pathological findings  
A total of 292 biopsies were obtained, of which 188 were routine, and 104 were for-cause. We 
compared Banff scores and pathological diagnosis rates between patients with MVI score ≥ 2 and 
those with MVI score < 2. These comparisons focused on T-cell mediated (TMR) and interstitial 
fibrosis/tubular atrophy within the first year following transplantation; we defined these pathologies 
according to the Banff criteria32. 
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In Table 2, pathological findings based on Banff criteria are compared between patients with high or 
low MVI scores. All Banff scores were significantly higher in patients with MVI score ≥ 2 (all p < 
0.05). C4d deposition (C4d score ≥ 2) was observed in a total of 126 recipients (85.1%), with 
comparable frequency between patients with low (83.8 %) and high MVI scores (90.3 %, p = 0.570). 
However, very high C4d scores (> 3) were significantly more frequent in patients with MVI score ≥ 2 
(51.6 %) than in patients with MVI score < 2 (19.7 %, p = 0.0009), along with TMR (p = 0.0001) and 
interstitial fibrosis/tubular atrophy (p = 0.0143).  
 
Graft function 
 Figure 4 illustrates mean serum eGFR for the two groups. Mean serum eGFR at 3 months was 40.0 
mL/min/1.73m2 in the MVI score ≥ 2 group and 45.6 mL/min/1.73m2 in the MVI score < 2 group. 
Mean serum eGFR between 3 months and 10 years was reduced by 3.7 mL/min/1.73m2 in the MVI 
score ≥ 2 group and increased by 5.5 mL/min/1.73m2 in the MVI score < 2 group. Throughout the 
study, serum eGFR was significantly inferior for patients with MVI score ≥ 2, relative to those with 
MVI score < 2 (p = 0.048).  
 
Graft survival according to MVI localization in patients with MVI score ≥ 2 
 To evaluate the impact of MVI localization on graft survival, we divided the patients into two 
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subgroups as follows: patients with peritubular capillaritis only (ptc score ≥ 2) and patients with 
glomerulitis (g score ≥ 1) and peritubular capillaritis (ptc score ≥ 1). Among 31 patients with MVI 
score ≥ 2, peritubular capillaritis was observed in 9 patients, while glomerulitis and peritubular 
capillaritis were both observed in the remaining 22. There were no significant differences in 5-year 
graft survival (Figure 5) between these patients (100.0 % vs. 85.9 %, Log-rank test p = 0.268; 
Wilcoxson’s test p = 0.269). No patient presented glomerulitis alone.  
 
Graft function according to MVI localization in patients with MVI score ≥ 2 
 Figure 6 illustrates mean serum eGFR for the two groups. Mean serum eGFR at 3 months was 40.6 
mL/min/1.73m2 in patients with peritubular capillaritis alone and 39.7 mL/min/1.73m2 in patients with 
both glomerulitis and peritubular capillaritis. Mean serum eGFR between 3 months and 8 years was 
increased by 8.5 mL/min/1.73m2 in patients with peritubular capillaritis alone and decreased by 3.0 
mL/min/1.73m2 in patients with both glomerulitis and peritubular capillaritis. Throughout the study, 
serum GFR did not differ significantly between these groups (p = 0.788).  
 
Prognostic indictors for MVI score ≥ 2  
 As shown in Table 3, univariate logistic regression indicated that predicators of MVI score ≥ 2 
include HLA class II mismatch (OR 4.85, p = 0.0038), C4d score (OR 2.45, p = 0.0039), and number 
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of biopsies (OR 11.4, p < 0.0001). Multivariate analysis also indicated that HLA class II mismatch 
(OR 5.10, p = 0.0093) was an independent predictor after adjusting for number of biopsies (OR 10.1, 
p < 0.0001). High C4d scores were also independently associated with MVI score, but not to a 
statistically significant extent (p = 0.0627). 
 
Discussion 
Previous studies have identified MVI score ≥ 2 as a risk factor for poor graft outcomes 19-21,27,28. For 
example, Sis et al. 21 reported that MVI in late biopsies may indicate AMR, whereas MVI in early 
biopsies often indicated antibody-independent pathologies, including TMR and acute tubular necrosis. 
Accordingly, they proposed a decision tree algorithm that includes C4d deposition as a marker to help 
diagnose AMR in early biopsies. However, this algorism is not suitable for use in ABOi transplantation, 
because C4d deposition is frequently observed 6,17,22. Notably, they also found that MVI score may 
predict graft loss independently of time, C4d deposition, and transplant glomerulopathy. Subsequently, 
de Kort et al.20 demonstrated that high MVI scores were significantly associated with poor graft 
survival and de novo DSA. However, the diagnostic value of MVI score ≥ 2 independent of preformed 
or de novo DSA is not clear for ABOi recipients.  
In this analysis, we demonstrate for the first time that MVI score ≥ 2 was significantly associated 
with poor graft outcome in patients who received kidney transplantation from ABOi living relatives, 
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regardless of C4d deposition. We note, however, that a high C4d score, i.e., C4d score 3, was 
associated with MVI score ≥ 2. In any case, graft survival and function were significantly lower soon 
after and years after transplantation in patients with MVI score ≥ 2, as indicated by Banff scores and 
other parameters, in line with Gupta et al. 33, who demonstrated that high MVI scores are associated 
with choric injury and inflammation. We also found that these patients were also more likely to develop 
TMR and interstitial fibrosis/tubular atrophy, as noted by Setoguchi et al.6, who reported that 
interstitial inflammation associated with interstitial fibrosis/tubular atrophy may negatively impact 
long-term graft outcome. Finally, we noted high i and t scores (tubulointerstitial inflammation) in 
patients with MVI score ≥ 2, perhaps confirming the observation by Couzi et al.23, who suggested that 
C4d deposition due to tubulointerstitial inflammation (i > 0 with or without tubulitis) was strongly 
associated with choric graft dysfunction in ABOi transplants. To further evaluate the impact of MVI 
score on graft outcome, we compared graft survival between patients with MVI score 0 and those with 
score 1. The influence of low magnitude MVI score such as 1 is unclear. We did not observe any 
significant differences between these two subgroups (data not shown). 
Meanwhile, we observed that localization of MVI either as peritubular capillaritis alone or in 
combination with glomerulitis, was not significantly associated with graft outcome, although this 
result is based on a relatively small size (N = 29). Nevertheless, we observed that graft outcome had a 
tendency to be worse among patients with peritubular capillaritis and glomerulitis, perhaps suggesting 
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that glomerulitis is a marker of graft dysfunction. Indeed, Couzi et al. 23 concluded that even mild 
glomerulitis was associated with poor graft function in ABOi transplants. Therefore, larger studies, 
ideally prospective, are needed to fully evaluate the impact of glomerulitis on graft outcome.  
Multivariate analysis revealed that HLA class II mismatch is an independent predictor of MVI score 
≥ 2, after adjustment for the number of biopsies. It is not surprising that the number of biopsies is a 
significant factor, because patients with high MVI (i.e., inferior graft function due to rejection) tend 
to receive more biopsies for diagnosis of rejection and further treatment. We removed the potential 
bias of this confounding factor by performing multivariate analysis, and HLA class II mismatch 
remained a significant predictor of high MVI. HLA class II mismatch may trigger class II DSA, and 
lead to AMR, however, this cohort was originally designed to exclude any effects of DSA. Indeed, de 
novo DSA following the first post-transplantation year was quite rare in this analysis. We believe that 
this rarity was caused by long-term B-cell depletion effects from our immunosuppressive protocols; 
our previous study indicated that B-cell depletion therapies, such as splenectomy or rituximab 
administration significantly reduced rates of de novo DSA and chronic AMR development 2 years 
after transplantation 34. In spite of this setting, HLA class II mismatch contributes to graft injury with 
high MVI, which leads to graft deteriorations such as interstitial fibrosis and tubular atrophy. One 
possibility is that mismatched HLA class II molecules elicit activation of CD4Th cells 35,36, resulting 
in TMR or graft injury. Indeed, TMR was more frequent among patients with MVI score ≥ 2, 
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highlighting the potential relationship between TMR and MVI outside and/or inside vessels in 
transplanted organs. For instance, Sis et al. 37 recently reported that in patients who were not highly 
sensitized, isolated endarteritis was a marker of acute TMR, and that isolated endarteritis was 
associated with poor graft outcome, as was endarteritis with TMR. In the end, high MVI scores 
represent heavy infiltration of immune cells into the microvasculature, tubules, and interstitium of the 
graft, so that such scores, in combination with TMR, eventually result in poor graft outcome, as seen 
in cases of mixed acute rejection. Indeed, our data might indicate that MVI score ≥ 2 captures some 
of the effects of TMR. This result is consistent, at least in part, with previous reports 21,37. In other 
words, it can be difficult to definitely distinguish between AMR and TMR, particularly during the 
early ABOi post-transplant period. According to Couzi et al.23, C4d deposition with tubulointerstitial 
inflammation in ABOi transplantation is associated with graft dysfunction, although these authors 
regard isolated C4d deposition and tubulointerstitial inflammation as benign. When high MVI is 
observed in ABOi transplantation, it is possible that even T-cell processes, supposedly moderate 
compared to AMR, mediate rejection, and should be treated accordingly with T-cell depletion 
therapies such as thymoglobulin.  
Multivariate analysis revealed that C4d score tends to predict MVI score. We observed C4d 
deposition in almost all patients (85.1 %) regardless of MVI score, in line with previous reports 6,17,22. 
Indeed, the high frequency of C4d deposition precludes its use as a marker for antibody-mediated 
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rejection in ABOi recipients. Accordingly, previous studies demonstrated that C4d deposition was not 
a key predictor of graft survival 20,21. Nevertheless, we demonstrate for the first time that a high C4d 
score, in particular C4d score 3, might be an independent predictor of MVI score ≥ 2. Thus, C4d scores 
should be carefully evaluated for its potential ability to effectively predict graft outcome in ABOi 
transplantation. 
Finally, our data revealed that anti-blood group IgG titers were not associated with MVI score ≥ 2, 
in line with our previous studies 10,11. However, other groups reported that early postoperative titers 
were biomarkers of antibody-mediated rejection 38. This discrepancy might be due to differences in 
analytical techniques. For example, we measure titers by agglutination and ELISA assays 39 while 
Tobian et al. 38 at John Hopkins Hospital used Marsh scoring and agglutination. Moreover, the 
mechanism of binding between carbohydrate antigens and antibodies remains unclear.  
This study was limited first by the retrospective design and the relatively small sample size. Second, 
the highest Banff and MVI scores observed within 1 year after transplantation were used, even though 
such scores were not necessarily obtained at the same time in some cases. Third, we did not evaluate 
non-HLA antibodies such as MHC class I chain-related gene A or B, and therefore, we cannot exclude 
the effects of these antibodies. Forth, we did not evaluate post-treatment changes to MVI score. 
Because the present study used only the maximum MVI score, it did not include subsequent MVI 
scores, which always decreased after treatment, or were unknown due to lack of a follow-up biopsy. 
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Further investigation of the relationship between post-treatment MVI score changes and graft outcome 
could improve treatments for high MVI after ABOi transplantation. Finally, because the present study 
was retrospective, we missed some biopsies following the first year post-transplantation (1-2 y post-
transplantation, the biopsy skip rate was 114/144 or 79.2%; 2-5 y, 98/134 or 73.1%; and > 5 y, 55/82 
or 67.1%). These missing long-term follow-up data may cause unavoidable bias, or mask detection of 
pathological diagnosis such as subclinical rejection.  
In summary, we found that MVI score ≥ 2 within 1 year after ABOi transplantation was a useful 
predictor of poor graft outcome, regardless of C4d deposition. Moreover, MVI score ≥ 2 was 
significantly associated with HLA class II mismatch, and tended to correlate with high C4d scores. 
Quick and proper treatment is required for acute rejection with MVI score ≥ 2, especially in the early 
ABOi post-transplant period. Because some impaired grafts with MVI score ≥ 2 exhibit cellular 
rejection, a new therapeutic approach such as T-cell system depression may be necessary. Thus, we 
suggest that MVI score ≥ 2 supports a diagnosis of AMR in ABOi transplantation. This conclusion 
should be confirmed for large patient populations from different transplant centers.  
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Table 1: Patient characteristics. 
 
Variable All (n = 148) MVI score < 2  (n = 117) MVI score ≥ 2 (n = 31) p-value 
Recipient age 46.6 ± 14.0  46.6 ± 14.1 46.7 ± 13.7 0.991 
Recipient sex 
 Male 
 Female 
 
96 (64.9%) 
52 (35.1%) 
 
75 (64.1%) 
42 (35.9%) 
 
21 (67.7%) 
10 (32.3%) 
0.833 
Kidney disease  
 Diabetes 
 ADPKD 
 IgA nephropathy 
 FSGS 
 Reflux nephropathy 
 Others 
 Unknown/CGN 
 
22 (14.9%) 
8 (5.41%) 
28 (18.9%) 
7 (4.73%) 
6 (4.05%) 
22 (14.9%) 
55 (37.2%) 
 
17 (14.5%) 
6 (5.13%) 
21 (17.9%) 
7 (5.98%) 
5 (4.27%) 
20 (17.1%) 
41 (35.0%) 
 
5 (16.1%) 
2 (6.45%) 
7 (3.23%) 
0  
1 (3.23%) 
2 (6.45%) 
14 (45.2%) 
0.986 
Duration of dialysis 44.6 ± 54.9 44.5 ± 54.1 45.1 ± 59.0 0.506 
Donor age 59.4 ± 9.34 59.3 ± 9.31 60.0 ± 9.59 0.814 
Donor sex 
 Male 
 Female 
 
47 (31.8%) 
101 (68.2%) 
 
40 (34.2%) 
77 (65.8%) 
 
7 (22.6%) 
24 (77.4%) 
0.280 
ABO groups 
 A to B 
 AB to B 
 A to O 
 B to A 
 AB to A 
 B to O 
AB to O 
 
28 (18.9%) 
14 (9.46%) 
45 (30.4%) 
11 (7.43%) 
17 (11.5%) 
31 (20.9%) 
2 (1.35%) 
 
21 (17.9%) 
11 (9.40%) 
34 (29.1%) 
11 (9.40%) 
15 (12.8%) 
23 (19.7%) 
2 (1.71%) 
 
7 (22.6%) 
3 (9.68%) 
11 (35.5%) 
0  
2 (6.45%) 
8 (25.8%) 
0 
0.498 
HLA class I mismatch 
 ≥ 3 
 < 3 
 
46 (31.1%) 
102 (68.9%) 
 
35 (29.9%) 
82 (70.1%) 
 
11 (35.5%) 
20 (64.5%) 
0.663 
HLA class II mismatch 
 ≥ 1 
 0 
 
105 (70.9%) 
43 (29.1%) 
 
77 (65.8%) 
40 (34.2%) 
 
28 (90.3%) 
3 (9.68%) 
0.0072 
BSX induction  
 With 
 
134 (90.5%) 
 
107 (91.5%) 
 
27 (87.1%) 
0.493 
28 
 
 Without 14 (9.50%) 10 (8.55%) 4 (12.9%) 
RTX induction  
 With 
 Without 
 
123 (83.1%) 
25 (16.9%) 
 
100 (85.5%) 
17 (14.5%) 
 
23 (74.2%) 
8 (25.8%) 
0.176 
SPX 
 With 
 Without 
 
30 (20.3%) 
118 (79.7%) 
 
21 (17.9%) 
96 (82.1%) 
 
9 (29.0%) 
22 (71.0%) 
0.209 
Preoperative DFPP 
 ≥ 4 
 < 4 
 
42 (28.4%) 
106 (71.6%) 
 
32 (27.4%) 
85 (72.6%) 
 
10 (32.3%) 
21 (67.7%) 
0.655 
Baseline anti-blood group IgG  
 ≥ 1: 128 
 < 1: 128 
 
36 (24.3%) 
112 (75.7%) 
 
25 (21.4%) 
92 (78.6%) 
 
11 (35.5%) 
20 (64.5%) 
0.156 
Preoperative anti-blood group IgG 
 ≥ 1: 32 
 < 1: 32 
 
23 (15.5%) 
125 (84.5%) 
 
17 (14.5%) 
100 (85.5%) 
 
6 (19.4%) 
25 (80.6%) 
0.578 
Postoperative anti-blood group IgG  
 ≥ 1: 64 
 < 1: 64 
 
13 (8.78%) 
135 (91.2%) 
 
9 (7.69%) 
108 (92.3%) 
 
4 (12.9%) 
27 (87.1%) 
0.362 
Total biopsies 
 ≥ 3 
 < 3 
 
26 (17.6%) 
122 (82.4%) 
 
10 (8.55%) 
107 (91.5%) 
 
16 (51.6%) 
15 (48.4%) 
<0.0001 
Years of follow-up 5.16 ± 4.06 5.09 ± 4.01  5.41 ± 4.32 0.790 
 
MVI, microvascular inflammation; ADPKD, autosomal dominant polycystic kidney disease;  FSGS, 
focal segmental glomerulosclerosis; CGN, chronic glomerular nephritis; HLA, human leukocyte antigen; 
BSX, basiliximab; RTX, rituximab; SPX, splenectomy; DFPP, double filtration plasmapheresis 
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Table 2: Correlation of MVI score with Banff scores and pathological diagnosis rate 
 
Pathological 
parameter 
All  
(n = 148) 
MVI score < 2  
(n = 117) 
MVI score ≥ 2 
(n = 31)  
p-value 
v 0.14 ± 0.45  0.068 ±0.34 0.39 ±0.67 <0.0001 
i 0.65 ±0.80 0.49 ±0.69 1.29 ±0.90 <0.0001 
t 0.38 ± 0.73 0.21 ± 0.55 1.00 ±0.97 <0.0001 
C4d  2.06 ±0.76 1.97 ±0.74 2.39 ±0.76 0.0019 
cg 0.061±0.29 0 0.29 ±0.59 <0.0001 
cv 0.081 ±0.38 0.051 ± 0.32 0.19 ± 0.54 0.0375 
ct 0.54 ±0.78 0.36 ±0.59 1.19 ± 1.01 <0.0001 
ci 0.55 ±0.76 0.38 ±0.60 1.19 ±0.95 <0.0001 
ah 0.52 ±0.72 0.45 ± 0.71 0.77 ± 0.72 0.0094 
TCMR 18 (12.2%) 8 (6.84%) 10 (32.2%) 0.0001 
IF/TA 37 (25.0%) 24 (20.5%) 13 (41.9%) 0.0143 
 
MVI, microvascular inflammation; TCMR, T cell-mediated rejection; IF/TA, interstitial fibrosis and 
tubular atrophy 
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Table 3: Univariate and multivariate logistic regression analyses of risk factors associated with MVI 
score ≥ 2. 
 
Variable Univariate  
OR 95%CI 
p-value Multivariate 
OR 95%CI 
p-value 
Recipient age, years  1.00 (0.97-1.03) 0.962 
  
Recipient sex 
 Male  
 Female 
 
Reference 
0.85 (0.52-2.82) 
0.705 
  
Donor age, years 1.01 (0.97-1.05) 0.702 
  
Donor sex 
 Male  
 Female  
 
Reference 
1.78 (0.74-4.80) 
0.206 
  
ABO group 
 A1 or A1B incompatible 
 Others  
 
1.51 (0.67-3.62) 
Reference 
0.326 
  
HLA class I mismatch 
 ≥ 3 
 < 3 
 
1.29 (0.55-2.94) 
Reference 
0.555 
  
HLA class II mismatch 
 ≥ 1 
 0 
 
4.85 (1.59-21.1) 
Reference 
0.0038  
5.10 (1.45-25.2) 
Reference 
0.0093 
BSX induction 
 With  
 Without 
 
0.63 (0.19-2.44) 
Reference 
0.477 
  
RTX induction 
 With 
 Without 
 
0.49 (0.19-1.32) 
Reference 
0.153 
  
Splenectomy 
 With 
 Without 
 
1.87 (0.73-4.56) 
Reference 
0.186 
  
Preoperative DFPP 
 ≥ 4 
 < 4 
 
1.26 (0.52-2.93) 
Reference 
0.593 
  
31 
 
Anti-blood group IgG at baseline 
 ≥ 1: 128  
 < 1: 128  
 
2.02 (0.84-4.74) 
Reference 
0.114 
  
Anti-blood group IgG at pre-transplant  
 ≥ 1: 32 
 < 1: 32 
 
1.41 (0.47-3.80) 
Reference 
0.519 
  
Anti-blood group IgG at post-transplant  
  ≥ 1: 64 
  < 1: 64 
 
1.78 (0.45-5.92) 
Reference 
0.383 
  
Total biopsies 
 ≥ 3 
 < 3 
 
11.4 (4.47-30.8) 
Reference 
<0.0001  
10.1 (3.73-29.4) 
Reference 
<0.0001 
C4d score 2.45 (1.31-4.92) 0.0039 1.88 (0.97-3.87) 0.0627 
 
MVI, microvascular inflammation; OR, odds ratio; CI, confidence interval; HLA, human leukocyte 
antigen; BSX, basiliximab; RTX, rituximab; SPX, splenectomy; DFPP, double filtration 
plasmapheresis 
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Figure legends  
Figure 1: Patient selection and study design 
 
Figure 2: Immunosuppressive and desensitization protocols for patients undergoing ABO-
incompatible transplantation at Tokyo Women’s Medical University.  
 
Figure 3: ABO-incompatible kidney graft survival in patients stratified according to MVI score ≥ 2. 
Survival rate was calculated using the Kaplan-Meier method, and compared using the log-rank test 
and Wilcoxon’s test, respectively (p = 0.0878, 0.0129). Solid line and dotted line show the survival 
rates and 95% confidence intervals, respectively.   
 
Figure 4: Mean serum eGFR in patients stratified according to MVI score ≥ 2. Serum eGFR was 
significantly inferior for patients with MVI score ≥ 2 relative to eGFR for those with MVI score < 2 
throughout the study (p = 0.048). Error bars indicate standard deviation. P-value was obtained using 
a mixed model test of trend profile. We excluded 2 patients with MVI ≥ 2 from this analysis because 
their grafts had been lost prior to 3 months after transplantation.  
 
Figure 5: ABO-incompatible kidney graft survival according to MVI localization in patients with MVI 
33 
 
score ≥ 2. Survival rate was calculated using the Kaplan-Meier method, and compared using the log-
rank test and Wilcoxon’s test, respectively (p = 0.268, 269). Solid line and dotted line indicate the 
survival rates and 95% confidence intervals, respectively.   
 
Figure 6: Mean serum eGFR according to MVI localization in patients with MVI score ≥ 2. Serum 
GFR did not differ significantly between patients with peritubular capillaritis alone and patients with 
both glomerulitis and peritubular capillaritis (p = 0.788). Error bars indicate standard deviation. P-
value was obtained using a mixed model test of trend profile. We excluded 2 patients with both 
glomerulitis and peritubular capillaritis from this analysis because their grafts had been lost prior to 3 
months after transplantation.  
 
Figure 1: Patient selection and study design
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Figure 2: Immunosuppressive and desensitization protocols for patients undergoing ABO-
incompatible transplantation at Tokyo Women’s Medical University.
0.10 mg/kg/day
MP
MMF
FK
-7 KTx 7 14 Day
DFPP
RTX 200 mg/body (2005 - current)
4
BSX 20 mg (2002 -)
Target trough: 
6-8 ng/mL 
Maintenance target trough: 
3-5 ng/mL
2,000 mg/day
1,000-1,500 mg/day
20 mg 20 mg
500
250 
125 
80 60 40
SPX (2001 - 2004)
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